China's National Medical Products Administration (NMPA) approved Shanghai Junshi Biosciences' (HKG:1877) new drug application (NDA) for its cholesterol ongericimab injection, according to a Sunday filing with the Hong Kon bourse.
The drug is meant for the treatment of adult patients with primary hypercholesterolemia (non-familial) and mixed dyslipidemia.
The pharmaceutical stocks were down nearly 5% in Hong Kong and 1% in Shanghai in recent trading.
Price (HKD): $14.58, Change: $-0.72, Percent Change: -4.71%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。